retifanlimab
Sponsor Briacell Therapeutics CORP. · listed as BCTX
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
retifanlimab is a clinical-stage drug asset sponsored by Briacell Therapeutics CORP., listed as BCTX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2027 (month precision, medium confidence), tied to trial NCT06072612. The asset is in Phase 3 and currently recruiting, studied in Breast Cancer.
Next catalyst
Event typeREADOUT
Expected date2027-12-31
As disclosedDec 2027
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06072612
PhasePHASE3
StatusRECRUITING
Lead sponsorBriaCell Therapeutics Corporation
Listed asBCTX
Condition(s)Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm; Breast Cancer Metastatic; End Stage Cancer
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More BCTX catalysts